Alex Zhavoronkov (Insilico)

'Longevi­ty as a ser­vice': In­sil­i­co spins off AI biotech that trains deep learn­ing on an­ti-ag­ing treat­ments

Since its in­cep­tion in 2014, In­sil­i­co has racked up deal af­ter deal on the promise that ar­ti­fi­cial in­tel­li­gence can has­ten drug de­vel­op­ment, tout­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.